S 3302119th CongressIn Committee
Mikaela Naylon Give Kids a Chance Act of 2025
Standard Summary
Balanced plain-English summary
This Senate bill amends the Federal Food, Drug, and Cosmetic Act to expand FDA authority and requirements for molecularly targeted pediatric cancer investigations, including combination drug studies, and extends the rare pediatric disease priority review voucher program through 2030. It also requires FDA guidance, reports to Congress, and a GAO study on voucher effectiveness.
Key Points
- 1Requires pediatric cancer investigations for certain molecularly targeted drugs and drug combinations.
- 2Clarifies FDA determination timing and applicability of pediatric study requirements.
- 3Extends rare pediatric disease priority review vouchers to September 30, 2030, and adjusts user fee timing.
- 4Mandates FDA guidance, an HHS report, and GAO studies on pediatric cancer drug development and vouchers.
Impact Areas
Pediatric cancer patientsDrug and biological product manufacturersFood and Drug AdministrationMedical researchersRare disease advocates
Generated by deepseek/deepseek-v4.1-flash-1017Nov 18, 2026